Quebec does not participate in the pCODR process and has its own review process. In Quebec, the Conseil du Médicaments makes the decision regarding medication coverage / reimbursement.
- Pharmaceutical companies can submit the required medication information to the Conseil du Médicaments for review.
- For 30 days from the medication submission date, stakeholder groups are given an opportunity to provide their opinions and concerns about the medication funding to the Conseil du Médicaments.
- The Conseil du Médicaments reviews the medication safety and cost and compares it to other medications funded by the province. After reviewing the information, the Conseil du Médicaments announces the decision regarding coverage / funding. Funding and coverage decision are announced three times annually.
Information taken from Brain Tumour Canada’s website